LivaNova PLC (LIVN) shares surged 10.64% in pre-market trading on Wednesday following the release of better-than-expected first-quarter results and encouraging data from a clinical study on sleep apnea treatment.
The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly higher than the expected $0.76. LivaNova also raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%.
Adding to the positive sentiment, LivaNova announced promising 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, along with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth in the sleep apnea market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.